Disease Information

General Information of the Disease (ID: DIS00209)

• Name: Fallopian tube cancer
• ICD: ICD-11: 2C74

Type(s) of Resistant Mechanism of This Disease

  EADR: Epigenetic Alteration of DNA, RNA or Protein

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Carboplatin

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Interleukin 6 receptor (IL6R) [1]

• Resistant Disease: Fallopian tube cancer [ICD-11: 2C74.0]
• Molecule Alteration: Expression; Up-regulation
• Resistant Drug: Carboplatin
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Fallopian tube cancer tissue; .
• Experiment for Molecule Alteration: ELISA assay
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: Our findings in the fallopian tube cancer and ovarian cancer cell lines showed that SKOV3 cells displayed 10-fold greater resistance to cisplatin and 5.8 times more resistance to carboplatin than A2780 cells. SKOV3 cells displayed platinum-induced IL-6 and IL-8 overproduction whereas wild type A2780 displayed no detectable cytokine production.

Key Molecule: Interleukin-8 (IL8) [1]

• Resistant Disease: Fallopian tube cancer [ICD-11: 2C74.0]
• Molecule Alteration: Expression; Up-regulation
• Resistant Drug: Carboplatin
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Fallopian tube cancer tissue; .
• Experiment for Molecule Alteration: ELISA assay
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: Our findings in the fallopian tube cancer and ovarian cancer cell lines showed that SKOV3 cells displayed 10-fold greater resistance to cisplatin and 5.8 times more resistance to carboplatin than A2780 cells. SKOV3 cells displayed platinum-induced IL-6 and IL-8 overproduction whereas wild type A2780 displayed no detectable cytokine production.

Preclinical Drug(s) 1 drug(s) in total

APR-246/Cisplatin

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Cellular tumor antigen p53 (TP53) [2]

• Sensitive Disease: Fallopian tube cancer [ICD-11: 2C74.0]
• Molecule Alteration: Missense mutation; p.C238F (c.713G>T)
• Sensitive Drug: APR-246/Cisplatin
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Ascitic fluid; .
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: FMCA assay

References

• Ref 1: Relationships of Ex-Vivo Drug Resistance Assay and Cytokine Production with Clinicopathological Features in the Primary Cell Culture of Thai Ovarian and Fallopian Tube Cancer Patients .Asian Pac J Cancer Prev. 2017 Nov 26;18(11):3063-3071. doi: 10.22034/APJCP.2017.18.11.3063. 10.22034/APJCP.2017.18.11.3063
• Ref 2: Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancerJ Ovarian Res. 2016 May 14;9(1):27. doi: 10.1186/s13048-016-0239-6.